Developer docs
API playgroundTry for free, no card

Search company profiles

FYR Bio

Full company profile

uuid003xaw4

Namestring
FYR Bio
Legal namestring
FYR Diagnostics, Inc.
Websiteurl
fyr.bio
Company typeenum
Private
Founded yearstring
-
Descriptiontext

FYR Bio (legal entity FYR Diagnostics, Inc.) is a private biotechnology company headquartered in Missoula, Montana, that operates an extracellular vesicle (EV)-based liquid biopsy platform called EV-Omics (EVO). The company's core differentiator is its proprietary SPARCs (Selective Protein Affinity Reagent Chemistries) enrichment technology, which isolates disease- or tissue-associated EV subpopulations from peripheral blood to solve the signal-to-noise problem that limits conventional liquid biopsy approaches. AI-enabled multiomic analytics then process RNA and protein data from these enriched vesicles to produce disease biomarkers, with peer-reviewed clinical validation showing 89% sensitivity and 100% specificity (AUC 0.99) for distinguishing adult malignant gliomas from healthy controls.

FYR operates as a B2B service provider serving pharmaceutical and biotech drug developers, academic medical centers, and clinical research programs. Primary applications are biomarker discovery, patient stratification, pharmacodynamic readouts, and treatment response monitoring across neuro-oncology (e.g., glioblastoma), neurodegeneration (e.g., Parkinson's disease), and broader solid tumor oncology. The company holds active CLIA certification (CLIA #27D2190551) and maintains HIPAA compliance, enabling clinical-grade diagnostic operations at its Montana laboratory. Named collaborations include NuvOx Therapeutics (Phase IIb RESTORE glioblastoma trial supported by an NCI SBIR grant) and Mayo Clinic (Parkinson's disease biomarkers). Compute infrastructure is provided through a CIQ Fuzzball integration that scales AI pipelines to production-grade throughput.

The business model is professional services-based: revenue is generated through custom project agreements with enterprise pharma and biotech partners, supplemented by non-dilutive SBIR grant funding. Pricing is not publicly disclosed and contracts operate on a multi-year, custom-tailored basis. The company was founded prior to 2021 and has raised approximately $8 million in venture capital as of September 2025 (Two Bear Capital, The Sontag Innovation Fund, Yuvaan Tiwari Foundation), plus a $1,976,897 NCI SBIR grant awarded in November 2025. Headcount is 11-50 employees and operations are U.S.-based, with go-to-market executed through direct business development outreach, scientific conference presentations, and peer-reviewed publications.

Short descriptiontext

FYR Bio is a private biotechnology company that provides AI-enabled liquid biopsy biomarker discovery and clinical trial support services to pharmaceutical, biotech, and academic medical center partners using its proprietary extracellular vesicle enrichment and multiomic analytics platform (EV-Omics).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMissoula, United States
HQ citystring
Missoula
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomarker discovery services, liquid biopsy technology, extracellular vesicle analysis, multiomic profiling services, clinical trial biomarker support
Industry5 codes
PRIMARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Biomarker Discovery Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Biomarker Discovery Services
TypeProfessional Services
Description

FYR provides biomarker discovery and validation services to pharmaceutical and biotech partners through collaborative research agreements. Services include analysis of patient blood samples using the EV-Omics platform to identify and validate disease biomarkers for clinical trial support and therapeutic development.

fyr.bio
2Clinical Trial Support
TypeProfessional Services
Description

The company supports clinical trials through longitudinal biomarker analysis, pharmacodynamic readouts, and patient stratification services. Revenue generated through service agreements with drug development companies participating in Phase IIb trials and other clinical programs.

fyr.bio
3SBIR Grant Funding
TypeProfessional Services
Description

Non-dilutive funding from Small Business Innovation Research (SBIR) grants, including a $1,976,897 Direct-to-Phase II award from the National Cancer Institute supporting the liquid biopsy collaboration with NuvOx Therapeutics in glioblastoma trials.

fyr.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom project-based pricing for pharmaceutical partners
ModelOtherBilling cadenceMulti-year contract
Notes

Services are tailored to partner requirements with custom data outputs and flexible engagement models. No public pricing tiers available.

fyr.bio
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

FYR Bio provides biomarker discovery and clinical trial support services to pharmaceutical and biotech partners through its EV-Omics (EVO) platform, which uses proprietary SPARCs enrichment technology and AI-enabled multiomic analysis of extracellular vesicles (EVs) from blood samples to identify RNA and protein biomarkers. The company's CLIA-certified laboratory supports longitudinal biomarker analysis, patient stratification, pharmacodynamic readouts, and treatment response monitoring across oncology, neuro-oncology, and neurodegeneration indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 89% sensitivity and 100% specificity (AUC 0.99) in distinguishing adult malignant gliomas from healthy controls using brain-derived EV protein panels
+2 more records
Product overview1 text field

FYR Bio offers a unified platform centered on its EV-Omics (EVO) technology, which combines proprietary SPARCs enrichment chemistry with AI-enabled multiomic analysis of extracellular vesicles from peripheral blood. The core EVO Platform serves as the primary discovery and detection engine for RNA and protein biomarkers, while SPARCs provides the foundational EV isolation technology that enables the platform to extract meaningful signals from the complex blood environment. Fuzzball (from CIQ) is integrated as a computational infrastructure layer that scales the EVO platform's analytics workflows for production-grade, reproducible biomarker discovery.

Product and service1 record
1EV-Omics (EVO) Platform
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

Clinical collaboration supported by $1,976,897 NCI Direct-to-Phase II SBIR grant. FYR integrates EV-based liquid biopsy technology into NuvOx's Phase IIb RESTORE trial of NanO2 in glioblastoma. Project aims to identify biomarkers that reflect hypoxia biology, correlate with treatment exposure, and help differentiate pseudoprogression from true progression.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-10-09
Description

Technology integration partnership where CIQ's Fuzzball performance computing platform powers FYR's analytics workflows. Fuzzball enables FYR to implement and scale AI pipelines at 100x throughput with production-quality reproducibility. Both companies are Two Bear Capital portfolio companies, enabling transformative innovation across the life sciences ecosystem.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-29
Description

Know-how agreement to advance blood-based biomarker solutions for Parkinson's disease research and clinical applications. Collaboration aims to generate data to deepen understanding of PD progression and subtypes, discover EV biomarkers associated with Parkinson's disease, and develop tools with clinical and commercial applications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Foundation Medicine (a Roche subsidiary) is a leading oncology molecular profiling and biopharma services company. It is a broad incumbent peer to FYR for pharma biomarker discovery and clinical trial companion diagnostic partnerships in oncology.

TypeDirect peer
Description

C2N Diagnostics commercializes blood-based biomarker assays for CNS disorders (e.g., PrecivityAD for Alzheimer's). It is a direct peer to FYR's Mayo Clinic Parkinson's program because both target CNS fluid biomarkers in blood, serving pharma and academic neurology customers.

TypeBroad incumbent
Description

Natera is a publicly-traded cell-free DNA and liquid biopsy company with oncology, transplant, and reproductive health franchises. It is a broad incumbent peer to FYR in the pharma services liquid biopsy market, particularly for oncology trial support.

TypeBroad incumbent
Description

Guardant Health is a leading liquid biopsy company with established pharma services (Guardant360, Reveal) for oncology. It is a broad incumbent peer to FYR's pharma biomarker services because it competes for the same pharma R&D and clinical trial biomarker budgets across oncology.

TypeDirect peer
Description

Quanterix offers ultra-sensitive protein biomarker measurement (Simoa) used in neuro-oncology and neurodegeneration research. It is directly comparable to FYR's EV-based proteomics discovery work, addressing similar pharma biomarker customers with blood-based immunoassay analytics.

TypeEmerging player
Description

Personalis provides tumor-informed liquid biopsy and molecular profiling services to oncology biopharma. It is an emerging player peer because it overlaps with FYR in pharma-facing multiomic biomarker services for oncology trials, but with a focus on ctDNA rather than EVs.

TypeBroad incumbent
Description

NeoGenomics operates oncology-focused clinical laboratory and pharma services (including biomarker discovery and CDx). It is a broad incumbent peer competing with FYR for pharma biomarker and clinical trial work in oncology.

TypeBroad incumbent
Description

Adaptive Biotechnologies operates a clonal sequencing biomarker platform serving pharma drug development and clinical diagnostics. It is a broad incumbent peer: it competes with FYR for pharma biomarker discovery budgets, and FYR's new COO previously led molecular lab operations at Adaptive.

TypeBroad incumbent
Description

Bio-Techne (including ExosomeDx) is a large life-sciences tools and diagnostics company with an EV-based diagnostics franchise (ExosomeDx). It is a broad incumbent peer: it competes in EV-based liquid biopsy for urology and oncology while offering a wider proteomics/reagents portfolio.

TypeBroad incumbent
Description

Caris Life Sciences offers molecular profiling and AI-driven biomarker analytics (MI Profile, MI Cancer Seek) to oncologists and biopharma. It is a broad incumbent peer in pharma multiomic biomarker discovery and clinical trial services, overlapping with FYR's oncology biomarker offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FYR Bio

Biomarker Discovery Servicesfyr.bio

FYR Bio is a private biotechnology company that provides AI-enabled liquid biopsy biomarker discovery and clinical trial support services to pharmaceutical, biotech, and academic medical center partners using its proprietary extracellular vesicle enrichment and multiomic analytics platform (EV-Omics).

What FYR Bio does

FYR Bio (legal entity FYR Diagnostics, Inc.) is a private biotechnology company headquartered in Missoula, Montana, that operates an extracellular vesicle (EV)-based liquid biopsy platform called EV-Omics (EVO). The company's core differentiator is its proprietary SPARCs (Selective Protein Affinity Reagent Chemistries) enrichment technology, which isolates disease- or tissue-associated EV subpopulations from peripheral blood to solve the signal-to-noise problem that limits conventional liquid biopsy approaches. AI-enabled multiomic analytics then process RNA and protein data from these enriched vesicles to produce disease biomarkers, with peer-reviewed clinical validation showing 89% sensitivity and 100% specificity (AUC 0.99) for distinguishing adult malignant gliomas from healthy controls.

FYR operates as a B2B service provider serving pharmaceutical and biotech drug developers, academic medical centers, and clinical research programs. Primary applications are biomarker discovery, patient stratification, pharmacodynamic readouts, and treatment response monitoring across neuro-oncology (e.g., glioblastoma), neurodegeneration (e.g., Parkinson's disease), and broader solid tumor oncology. The company holds active CLIA certification (CLIA #27D2190551) and maintains HIPAA compliance, enabling clinical-grade diagnostic operations at its Montana laboratory. Named collaborations include NuvOx Therapeutics (Phase IIb RESTORE glioblastoma trial supported by an NCI SBIR grant) and Mayo Clinic (Parkinson's disease biomarkers). Compute infrastructure is provided through a CIQ Fuzzball integration that scales AI pipelines to production-grade throughput.

The business model is professional services-based: revenue is generated through custom project agreements with enterprise pharma and biotech partners, supplemented by non-dilutive SBIR grant funding. Pricing is not publicly disclosed and contracts operate on a multi-year, custom-tailored basis. The company was founded prior to 2021 and has raised approximately $8 million in venture capital as of September 2025 (Two Bear Capital, The Sontag Innovation Fund, Yuvaan Tiwari Foundation), plus a $1,976,897 NCI SBIR grant awarded in November 2025. Headcount is 11-50 employees and operations are U.S.-based, with go-to-market executed through direct business development outreach, scientific conference presentations, and peer-reviewed publications.

FYR Bio firmographics

Firmographics
Name
FYR Bio
Legal name
FYR Diagnostics, Inc.
Website
https://fyr.bio
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
FYR Bio is a private biotechnology company that provides AI-enabled liquid biopsy biomarker discovery and clinical trial support services to pharmaceutical, biotech, and academic medical center partners using its proprietary extracellular vesicle enrichment and multiomic analytics platform (EV-Omics).
Ownership category
akta.pro rank

FYR Bio industry classification

Industry
Product category
Biomarker Discovery Services
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Biomarker discovery services
  • Liquid biopsy technology
  • Extracellular vesicle analysis
  • Multiomic profiling services
  • Clinical trial biomarker support

Where FYR Bio is headquartered

Location

Headquarters

HQ city
Missoula
HQ country
United States
HQ region
North America

Offices1 record

Markets served

FYR Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biomarker Discovery Services: FYR provides biomarker discovery and validation services to pharmaceutical and biotech partners through collaborative research agreements. Services include analysis of patient blood samples using the EV-Omics platform to identify and validate disease biomarkers for clinical trial support and therapeutic development.
  2. Clinical Trial Support: The company supports clinical trials through longitudinal biomarker analysis, pharmacodynamic readouts, and patient stratification services. Revenue generated through service agreements with drug development companies participating in Phase IIb trials and other clinical programs.
  3. SBIR Grant Funding: Non-dilutive funding from Small Business Innovation Research (SBIR) grants, including a $1,976,897 Direct-to-Phase II award from the National Cancer Institute supporting the liquid biopsy collaboration with NuvOx Therapeutics in glioblastoma trials.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for pharmaceutical partners

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

FYR Bio product offering

Product offering

Core offering

FYR Bio provides biomarker discovery and clinical trial support services to pharmaceutical and biotech partners through its EV-Omics (EVO) platform, which uses proprietary SPARCs enrichment technology and AI-enabled multiomic analysis of extracellular vesicles (EVs) from blood samples to identify RNA and protein biomarkers. The company's CLIA-certified laboratory supports longitudinal biomarker analysis, patient stratification, pharmacodynamic readouts, and treatment response monitoring across oncology, neuro-oncology, and neurodegeneration indications.

Product overview

FYR Bio offers a unified platform centered on its EV-Omics (EVO) technology, which combines proprietary SPARCs enrichment chemistry with AI-enabled multiomic analysis of extracellular vesicles from peripheral blood. The core EVO Platform serves as the primary discovery and detection engine for RNA and protein biomarkers, while SPARCs provides the foundational EV isolation technology that enables the platform to extract meaningful signals from the complex blood environment. Fuzzball (from CIQ) is integrated as a computational infrastructure layer that scales the EVO platform's analytics workflows for production-grade, reproducible biomarker discovery.

Differentiator

Problem solved

Functional benefit

Products and services

  • EV-Omics (EVO) Platform

Quantifiable outcome

  • 89% sensitivity and 100% specificity (AUC 0.99) in distinguishing adult malignant gliomas from healthy controls using brain-derived EV protein panels
  • +2 more outcomes

Companies that use FYR Bio

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

FYR Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

FYR Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and major.

  • NuvOx TherapeuticscoreStrategic or Co-development Partner · 19 November 2025Clinical collaboration supported by $1,976,897 NCI Direct-to-Phase II SBIR grant. FYR integrates EV-based liquid biopsy technology into NuvOx's Phase IIb RESTORE trial of NanO2 in glioblastoma. Project aims to identify biomarkers that reflect hypoxia biology, correlate with treatment exposure, and help differentiate pseudoprogression from true progression.
  • CIQmajorTechnology or Integration · 9 October 2025Technology integration partnership where CIQ's Fuzzball performance computing platform powers FYR's analytics workflows. Fuzzball enables FYR to implement and scale AI pipelines at 100x throughput with production-quality reproducibility. Both companies are Two Bear Capital portfolio companies, enabling transformative innovation across the life sciences ecosystem.
  • Mayo CliniccoreStrategic or Co-development Partner · 29 April 2025Know-how agreement to advance blood-based biomarker solutions for Parkinson's disease research and clinical applications. Collaboration aims to generate data to deepen understanding of PD progression and subtypes, discover EV biomarkers associated with Parkinson's disease, and develop tools with clinical and commercial applications.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

FYR Bio competitors and assessment

Company assessment

Broad incumbents

  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) is a leading oncology molecular profiling and biopharma services company. It is a broad incumbent peer to FYR for pharma biomarker discovery and clinical trial companion diagnostic partnerships in oncology.
  • Natera: Natera is a publicly-traded cell-free DNA and liquid biopsy company with oncology, transplant, and reproductive health franchises. It is a broad incumbent peer to FYR in the pharma services liquid biopsy market, particularly for oncology trial support.
  • Guardant Health: Guardant Health is a leading liquid biopsy company with established pharma services (Guardant360, Reveal) for oncology. It is a broad incumbent peer to FYR's pharma biomarker services because it competes for the same pharma R&D and clinical trial biomarker budgets across oncology.
  • NeoGenomics: NeoGenomics operates oncology-focused clinical laboratory and pharma services (including biomarker discovery and CDx). It is a broad incumbent peer competing with FYR for pharma biomarker and clinical trial work in oncology.
  • Adaptive Biotechnologies: Adaptive Biotechnologies operates a clonal sequencing biomarker platform serving pharma drug development and clinical diagnostics. It is a broad incumbent peer: it competes with FYR for pharma biomarker discovery budgets, and FYR's new COO previously led molecular lab operations at Adaptive.
  • Bio-Techne: Bio-Techne (including ExosomeDx) is a large life-sciences tools and diagnostics company with an EV-based diagnostics franchise (ExosomeDx). It is a broad incumbent peer: it competes in EV-based liquid biopsy for urology and oncology while offering a wider proteomics/reagents portfolio.
  • Caris Life Sciences: Caris Life Sciences offers molecular profiling and AI-driven biomarker analytics (MI Profile, MI Cancer Seek) to oncologists and biopharma. It is a broad incumbent peer in pharma multiomic biomarker discovery and clinical trial services, overlapping with FYR's oncology biomarker offering.

Direct peers

  • C2N Diagnostics: C2N Diagnostics commercializes blood-based biomarker assays for CNS disorders (e.g., PrecivityAD for Alzheimer's). It is a direct peer to FYR's Mayo Clinic Parkinson's program because both target CNS fluid biomarkers in blood, serving pharma and academic neurology customers.
  • Quanterix: Quanterix offers ultra-sensitive protein biomarker measurement (Simoa) used in neuro-oncology and neurodegeneration research. It is directly comparable to FYR's EV-based proteomics discovery work, addressing similar pharma biomarker customers with blood-based immunoassay analytics.

Emerging players

  • Personalis: Personalis provides tumor-informed liquid biopsy and molecular profiling services to oncology biopharma. It is an emerging player peer because it overlaps with FYR in pharma-facing multiomic biomarker services for oncology trials, but with a focus on ctDNA rather than EVs.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

FYR Bio social profiles

Digital presence

FYR Bio compliance and trust

Trust signal

Compliance2 records

FYR Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FYR Bio leadership team

Management profile

Number of profiles

Profiles10 records

FYR Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FYR Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FYR Bio

What does FYR Bio do?

FYR Bio provides biomarker discovery and clinical trial support services to pharmaceutical and biotech partners through its EV-Omics (EVO) platform, which uses proprietary SPARCs enrichment technology and AI-enabled multiomic analysis of extracellular vesicles (EVs) from blood samples to identify RNA and protein biomarkers. The company's CLIA-certified laboratory supports longitudinal biomarker analysis, patient stratification, pharmacodynamic readouts, and treatment response monitoring across oncology, neuro-oncology, and neurodegeneration indications.

Is FYR Bio a public or private company?

FYR Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was FYR Bio founded?

FYR Bio was founded in -1. It employs 11 to 50 people.

Where is FYR Bio based?

FYR Bio is headquartered in Missoula, United States, in the North America region.

How does FYR Bio make money?

Three revenue lines are on record. Biomarker Discovery Services are the primary driver. The others are clinical Trial Support and SBIR Grant Funding.

Who are FYR Bio's main competitors?

Broad incumbents on record are Foundation Medicine, Natera, Guardant Health, NeoGenomics, Adaptive Biotechnologies, Bio-Techne and Caris Life Sciences. Direct peers are C2N Diagnostics and Quanterix. Personalis is listed as an emerging player.

Does FYR Bio have an API?

No public API is recorded for FYR Bio.

What industry is FYR Bio in?

FYR Bio's product category is Biomarker Discovery Services. Its primary akta.pro industry code is HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceFYR Bio Appoints Barbara K. Zehentner, MBA, PhD, HCLD (ABB), as Chief Operating OfficerFYR Bio announced the appointment of Barbara K. Zehentner as Chief Operating Officer to lead the company's operational strategy and execution as it scales its EV-Omics platform. Zehentner brings more than two decades of experience in high-complexity laboratory operations, most recently serving as COO at CareNexa LLC dba Molecular Testing Labs and previously as Vice President of Molecular Laboratory Operations at Adaptive Biotechnologies. The appointment is intended to support FYR's expansion of laboratory capacity and partnerships across neuroscience and oncology.PR NewswireFYR Bio Appoints Barbara K. Zehentner, MBA, PhD, HCLD (ABB), as Chief Operating OfficerFYR Bio, a biotechnology company focused on extracellular vesicle-based multiomic insights, announced the appointment of Barbara K. Zehentner as Chief Operating Officer. Zehentner brings over two decades of laboratory operations experience, most recently serving as COO at CareNexa LLC dba Molecular Testing Labs and previously as Vice President of Molecular Laboratory Operations at Adaptive Biotechnologies. She will lead FYR's operational strategy and execution as the company scales its EV-Omics platform and expands laboratory capacity across neuroscience and oncology partnerships.BioSpaceFYR Bio and NuvOx Therapeutics Awarded NCI Direct-to-Phase II SBIR Grant to Advance Liquid-Biopsy Collaboration in Phase IIb Glioblastoma TrialFYR Bio and NuvOx Therapeutics have been awarded a $1.98 million grant from the National Cancer Institute to collaborate on integrating FYR's liquid-biopsy technology into NuvOx's Phase IIb glioblastoma trial. This partnership aims to use extracellular-vesicle biomarkers to help distinguish pseudoprogression from true tumor progression during treatment with NuvOx's NanO₂ radiosensitizer. The initiative is designed to de-risk NuvOx's clinical development program and refine future trial strategies.YahooFYR Bio and NuvOx Therapeutics Awarded NCI Direct-to-Phase II SBIR Grant to Advance Liquid-Biopsy Collaboration in Phase IIb Glioblastoma TrialFYR Bio and NuvOx Therapeutics received a two-year $1,976,897 NCI SBIR grant to integrate FYR's EV-based liquid-biopsy platform into NuvOx's Phase IIb glioblastoma trial. The collaboration will analyze plasma samples to identify hypoxia-related biomarkers and distinguish pseudoprogression from true progression.FyrFYR Bio and NuvOx Therapeutics Awarded NCI Direct-to-Phase II SBIR Grant to Advance Liquid-Biopsy Collaboration in Phase IIb Glioblastoma TrialFYR Bio announced a collaboration with NuvOx Therapeutics backed by a two-year $1,976,897 Direct-to-Phase II SBIR grant from the National Cancer Institute to integrate liquid-biopsy technology into NuvOx's Phase IIb glioblastoma trial. The funding will support FYR's EV-Omics platform in analyzing blood samples from NuvOx's RESTORE trial to discover hypoxia-related biomarkers that could differentiate pseudoprogression from true tumor progression. This collaboration aims to de-risk NuvOx's clinical development and inform future trial design and patient selection strategies.PR NewswireFYR Bio and NuvOx Therapeutics Awarded NCI Direct-to-Phase II SBIR Grant to Advance Liquid-Biopsy Collaboration in Phase IIb Glioblastoma TrialFYR Bio announced a collaboration with NuvOx Therapeutics supported by a two-year $1,976,897 Direct-to-Phase II SBIR grant from the National Cancer Institute (NCI). The grant will enable FYR to integrate its EV-Omics liquid-biopsy platform into NuvOx's Phase IIb RESTORE glioblastoma trial, exploring extracellular-vesicle biomarkers to differentiate pseudoprogression from true progression in patients. This funding aims to de-risk NuvOx's therapeutic development and generate multiomic insights to inform future clinical trial design and patient selection.AI InsiderFYR Integrates CIQ Fuzzball to Scale AI-Enabled Multiomic Platform And Accelerate Precision MedicineFYR selected CIQ's Fuzzball high-performance computing platform to power analytics workflows for its AI-driven EV-Omics precision medicine platform. The integration enables scalable, reproducible pipelines for biomarker discovery and drug development, with CIQ environments deployable in an hour. Both companies are backed by Two Bear Capital.PR NewswireFYR Integrates CIQ Fuzzball to Scale AI-Enabled Multiomic Platform and Accelerate Breakthroughs in Precision MedicineFYR selected CIQ's Fuzzball platform to scale its EV-Omics AI-enabled multiomic analytics, enabling production-ready pipelines in hours. The partnership, both portfolio companies of Two Bear Capital, aims to accelerate biomarker discovery and precision medicine. Fuzzball provides reproducibility for regulated environments like GLP and FDA.Pulse 2.0FYR Bio: $8 Million Closed To Advance Cancer And Brain Disease ResearchFYR Bio, a biotechnology company developing precision medicine tools through extracellular vesicle research, has completed an $8 million financing round with participation from The Sontag Innovation Fund, Yuvaan Tiwari Foundation, and existing investor Two Bear Capital. The funding will accelerate the company's oncology programs and expand its neuroscience focus, including neuro-oncology and neurodegeneration research. The company recently presented data at the Society for Neuro-Oncology Annual Meeting demonstrating its blood-based AI technology achieved 100% specificity and 89% sensitivity in differentiating adult malignant gliomas from healthy individuals.